{{Rsnum
|rsid=4770877
|Gene=ATP8A2
|Chromosome=13
|position=25761432
|Orientation=plus
|GMAF=0.4853
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ATP8A2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 8.0 | 46.0 | 46.0
| HCB | 27.7 | 43.1 | 29.2
| JPT | 28.3 | 47.8 | 23.9
| YRI | 49.0 | 42.9 | 8.2
| ASW | 29.8 | 57.9 | 12.3
| CHB | 27.7 | 43.1 | 29.2
| CHD | 29.4 | 42.2 | 28.4
| GIH | 8.9 | 37.6 | 53.5
| LWK | 68.2 | 28.2 | 3.6
| MEX | 31.0 | 51.7 | 17.2
| MKK | 53.2 | 39.7 | 7.1
| TSI | 6.9 | 45.1 | 48.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4770877
|Name_s=
|Gene_s=ATP8A2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00008. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109324
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4770877
|overall_frequency_n=67
|overall_frequency_d=126
|overall_frequency=0.531746
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=52
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}